The heparin-neutralizing factor (PF4) has been isolated from the supernatant of thrombin-treated, washed human blood platelets. The major part of the factor is present as a PF4-proteoglycan complex which can be dissociated at higher ionic strength. PF4 thus obtained is a basic protein of molecular weight 29,700. The carrier proteoglycan will recombíne with a maximum of 4 molecules of PF4, whereby dimerization of the resulting complex is observed. This is in contrast to the naturally occurring, released complex, which has a sedimentation constant which is rather compatible with the presence of monomeric material. Heparin displaces PF4 from its proteoglycan carrier; thereby a 1:1 heparin PF4 complex is formed. Contrary to preparations obtained by zinc precipitation, neither the PF4-carrier complex, nor purified PF4 obtained by dissociation at high ionic strength form insoluble complexes with fibrinogen or with complexes formed from fibrin-monomers and fibrinogen degradation products. Pretreatment of zinc-precipitated PF4 with EDTA abolishes its paracoagulating properties.

Keywords:
Blood platelets, Heparin-neutralizing factor, Platelet factor 4, Proteoglycan, Complex formation, Fibrinogen, Fibrin-monomer, complexes, Platelet aggregation
This content is only available via PDF.
© 1972 S. Karger AG, Basel
1972
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.